Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 10 of 117

Publication Record


Metabolic responses to exogenous ghrelin in obesity and early after Roux-en-Y gastric bypass in humans.
Tamboli RA, Antoun J, Sidani RM, Clements A, Harmata EE, Marks-Shulman P, Gaylinn BD, Williams B, Clements RH, Albaugh VL, Abumrad NN
(2017) Diabetes Obes Metab 19: 1267-1275
MeSH Terms: Acylation, Anti-Obesity Agents, Cohort Studies, Combined Modality Therapy, Cross-Over Studies, Energy Metabolism, Gastric Bypass, Ghrelin, Gluconeogenesis, Glucose Clamp Technique, Human Growth Hormone, Humans, Infusions, Intravenous, Insulin Resistance, Liver, Muscle, Skeletal, Obesity, Morbid, Pancreatic Polypeptide, Pancreatic Polypeptide-Secreting Cells, Pituitary Gland, Anterior, Postoperative Care, Preoperative Care, Protein Precursors, Single-Blind Method
Show Abstract · Added April 3, 2017
AIMS - Ghrelin is a gastric-derived hormone that stimulates growth hormone (GH) secretion and has a multi-faceted role in the regulation of energy homeostasis, including glucose metabolism. Circulating ghrelin concentrations are modulated in response to nutritional status, but responses to ghrelin in altered metabolic states are poorly understood. We investigated the metabolic effects of ghrelin in obesity and early after Roux-en-Y gastric bypass (RYGB).
MATERIALS AND METHODS - We assessed central and peripheral metabolic responses to acyl ghrelin infusion (1 pmol kg  min ) in healthy, lean subjects (n = 9) and non-diabetic, obese subjects (n = 9) before and 2 weeks after RYGB. Central responses were assessed by GH and pancreatic polypeptide (surrogate for vagal activity) secretion. Peripheral responses were assessed by hepatic and skeletal muscle insulin sensitivity during a hyperinsulinaemic-euglycaemic clamp.
RESULTS - Ghrelin-stimulated GH secretion was attenuated in obese subjects, but was restored by RYGB to a response similar to that of lean subjects. The heightened pancreatic polypeptide response to ghrelin infusion in the obese was attenuated after RYGB. Hepatic glucose production and hepatic insulin sensitivity were not altered by ghrelin infusion in RYGB subjects. Skeletal muscle insulin sensitivity was impaired to a similar degree in lean, obese and post-RYGB individuals in response to ghrelin infusion.
CONCLUSIONS - These data suggest that obesity is characterized by abnormal central, but not peripheral, responsiveness to ghrelin that can be restored early after RYGB before significant weight loss. Further work is necessary to fully elucidate the role of ghrelin in the metabolic changes that occur in obesity and following RYGB.
© 2017 John Wiley & Sons Ltd.
0 Communities
3 Members
0 Resources
24 MeSH Terms
Neither vaginal nor buccal administration of 800 μg misoprostol alters mucosal and systemic immune activation or the cervicovaginal microbiome: a pilot study.
Kalams SA, Rogers LM, Smith RM, Barnett L, Crumbo K, Sumner S, Prashad N, Rybczyk K, Milne G, Dowd SE, Chong E, Winikoff B, Aronoff DM
(2016) Eur J Contracept Reprod Health Care 21: 436-442
MeSH Terms: Abortifacient Agents, Nonsteroidal, Administration, Buccal, Administration, Intravaginal, Cervix Uteri, Cross-Over Studies, Elafin, Enzyme-Linked Immunosorbent Assay, Female, Humans, Immune System, Lymphocytes, Microbiota, Misoprostol, Pilot Projects, United States, Vagina
Show Abstract · Added June 2, 2017
OBJECTIVES - The aim of the study was to assess the extent to which misoprostol alters mucosal or systemic immune responses following either buccal or vaginal administration.
METHODS - This was a prospective, crossover pilot study of 15 healthy, reproductive-age women. Women first received 800 μg misoprostol either via buccal or vaginal administration and were crossed over 1 month later to receive the drug via the other route. Cervicovaginal lavage samples, cervical Cytobrush samples, cervicovaginal swabs, urine and blood were obtained immediately prior to drug administration and the following day. Parameters assessed included urine and cervicovaginal misoprostol levels, whole blood cytokine responses (by ELISA) to immune stimulation with lipopolysaccharide, peripheral blood and cervical lymphocyte phenotyping by flow cytometry, cervicovaginal antimicrobial peptide measurement by ELISA and vaginal microbial ecology assessment by 16S rRNA sequencing.
RESULTS - Neither buccal nor vaginal misoprostol significantly altered local or systemic immune and microbiological parameters.
CONCLUSION - In this pilot study, we did not observe significant alteration of mucosal or systemic immunology or vaginal microbial ecology 1 day after drug administration following either the buccal or vaginal route.
0 Communities
1 Members
0 Resources
16 MeSH Terms
Autonomic Blockade Reverses Endothelial Dysfunction in Obesity-Associated Hypertension.
Gamboa A, Figueroa R, Paranjape SY, Farley G, Diedrich A, Biaggioni I
(2016) Hypertension 68: 1004-10
MeSH Terms: Autonomic Nerve Block, Blood Pressure Determination, Body Mass Index, Comorbidity, Cross-Over Studies, Disease Progression, Endothelium, Vascular, Female, Follow-Up Studies, Humans, Hypertension, Male, Middle Aged, Nitric Oxide, Nitroprusside, Obesity, Risk Assessment, Severity of Illness Index
Show Abstract · Added October 14, 2016
Impaired nitric oxide (NO) vasodilation (endothelial dysfunction) is associated with obesity and thought to be a factor in the development of hypertension. We previously found that NO synthesis inhibition had similar pressor effects in obese hypertensives compared with healthy control during autonomic blockade, suggesting that impaired NO vasodilation is secondary to sympathetic activation. We tested this hypothesis by determining the effect of autonomic blockade (trimethaphan 4 mg/min IV) on NO-mediated vasodilation (increase in forearm blood flow to intrabrachial acetylcholine) compared with endothelial-independent vasodilation (intrabrachial sodium nitroprusside) in obese hypertensive subjects (30© 2016 American Heart Association, Inc.
0 Communities
1 Members
0 Resources
18 MeSH Terms
Angiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis--a randomized cross-over study.
Gamboa JL, Pretorius M, Sprinkel KC, Brown NJ, Ikizler TA
(2015) BMC Nephrol 16: 167
MeSH Terms: Angiotensin II Type 1 Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors, Arginine, Bradykinin, Cell Line, Cross-Over Studies, Double-Blind Method, Endothelium, Vascular, Female, Humans, Kidney Failure, Chronic, Male, Middle Aged, Ramipril, Renal Dialysis, Valsartan
Show Abstract · Added November 5, 2015
BACKGROUND - Endothelial dysfunction occurs in patients with end-stage renal disease (ESRD) and is associated with increased cardiovascular morbidity and mortality. Asymmetric dimethylarginine (ADMA) contributes to endothelial dysfunction in ESRD. In the general population, angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) decrease ADMA levels, but no study has compared the effect of these drugs in patients with ESRD on maintenance hemodialysis (MHD).
METHODS - We evaluated the effect of 1-week treatment with ramipril (5 mg/d), valsartan (160 mg/d), and placebo on ADMA levels in 15 patients on MHD in a double-blind, placebo-controlled, three x three cross-over study.
RESULTS - We found that ADMA levels were increased at baseline and throughout the dialysis session during ramipril treatment (p < 0.001 compared to both, placebo and valsartan). Ramipril did not increase ADMA levels in a study of patients without ESRD, suggesting that factors related to ESRD or hemodialysis contribute to the ACE inhibitor-induced increase in ADMA. We have previously shown that ACE inhibition increases bradykinin (BK) levels during hemodialysis. We therefore evaluated the effect of bradykinin on ADMA production in A549 cells; a cell line that expresses BK receptors. Incubation with BK increased intracellular ADMA concentration through BK B2-receptor stimulation.
CONCLUSION - These data indicate that short-term ACE inhibition increases ADMA in patients on MHD whereas ARBs do not. In vitro studies further suggest that this may occur through BK-mediated increase in ADMA production during ACE inhibition.
TRIAL REGISTRATION - Clinicaltrials.gov NCT00732069 August 6 2008 and NCT00607672 February 4 2008.
0 Communities
3 Members
0 Resources
16 MeSH Terms
Activation of the Endogenous Renin-Angiotensin-Aldosterone System or Aldosterone Administration Increases Urinary Exosomal Sodium Channel Excretion.
Qi Y, Wang X, Rose KL, MacDonald WH, Zhang B, Schey KL, Luther JM
(2016) J Am Soc Nephrol 27: 646-56
MeSH Terms: Adult, Aldosterone, Cross-Over Studies, Epithelial Sodium Channels, Exosomes, Female, Humans, Male, Renin-Angiotensin System, Sodium, Dietary
Show Abstract · Added November 30, 2015
Urinary exosomes secreted by multiple cell types in the kidney may participate in intercellular signaling and provide an enriched source of kidney-specific proteins for biomarker discovery. Factors that alter the exosomal protein content remain unknown. To determine whether endogenous and exogenous hormones modify urinary exosomal protein content, we analyzed samples from 14 mildly hypertensive patients in a crossover study during a high-sodium (HS, 160 mmol/d) diet and low-sodium (LS, 20 mmol/d) diet to activate the endogenous renin-angiotensin-aldosterone system. We further analyzed selected exosomal protein content in a separate cohort of healthy persons receiving intravenous aldosterone (0.7 μg/kg per hour for 10 hours) versus vehicle infusion. The LS diet increased plasma renin activity and aldosterone concentration, whereas aldosterone infusion increased only aldosterone concentration. Protein analysis of paired urine exosome samples by liquid chromatography-tandem mass spectrometry-based multidimensional protein identification technology detected 2775 unique proteins, of which 316 exhibited significantly altered abundance during LS diet. Sodium chloride cotransporter (NCC) and α- and γ-epithelial sodium channel (ENaC) subunits from the discovery set were verified using targeted multiple reaction monitoring mass spectrometry quantified with isotope-labeled peptide standards. Dietary sodium restriction or acute aldosterone infusion similarly increased urine exosomal γENaC[112-122] peptide concentrations nearly 20-fold, which correlated with plasma aldosterone concentration and urinary Na/K ratio. Urine exosomal NCC and αENaC concentrations were relatively unchanged during these interventions. We conclude that urinary exosome content is altered by renin-angiotensin-aldosterone system activation. Urinary measurement of exosomal γENaC[112-122] concentration may provide a useful biomarker of ENaC activation in future clinical studies.
Copyright © 2016 by the American Society of Nephrology.
0 Communities
3 Members
0 Resources
10 MeSH Terms
RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals.
Chen KY, Muniyappa R, Abel BS, Mullins KP, Staker P, Brychta RJ, Zhao X, Ring M, Psota TL, Cone RD, Panaro BL, Gottesdiener KM, Van der Ploeg LH, Reitman ML, Skarulis MC
(2015) J Clin Endocrinol Metab 100: 1639-45
MeSH Terms: Adult, Anti-Obesity Agents, Combined Modality Therapy, Cross-Over Studies, Double-Blind Method, Energy Metabolism, Female, Humans, Male, Middle Aged, Obesity, Receptor, Melanocortin, Type 4, Rest, Weight Reduction Programs, Young Adult, alpha-MSH
Show Abstract · Added February 4, 2016
CONTEXT - Activation of the melanocortin-4 receptor (MC4R) with the synthetic agonist RM-493 decreases body weight and increases energy expenditure (EE) in nonhuman primates. The effects of MC4R agonists on EE in humans have not been examined to date.
OBJECTIVE, DESIGN, AND SETTING - In a randomized, double-blind, placebo-controlled, crossover study, we examined the effects of the MC4R agonist RM-493 on resting energy expenditure (REE) in obese subjects in an inpatient setting.
STUDY PARTICIPANTS AND METHODS - Twelve healthy adults (6 men and 6 women) with body mass index of 35.7 ± 2.9 kg/m(2) (mean ± SD) received RM-493 (1 mg/24 h) or placebo by continuous subcutaneous infusion over 72 hours, followed immediately by crossover to the alternate treatment. All subjects received a weight-maintenance diet (50% carbohydrate, 30% fat, and 20% protein) and performed 30 minutes of standardized exercise daily. Continuous EE was measured on the third treatment day in a room calorimeter, and REE in the fasting state was defined as the mean of 2 30-minute resting periods.
RESULTS - RM-493 increased REE vs placebo by 6.4% (95% confidence interval, 0.68-13.02%), on average by 111 kcal/24 h (95% confidence interval, 15-207 kcal, P = .03). Total daily EE trended higher, whereas the thermic effect of a test meal and exercise EE did not differ significantly. The 23-hour nonexercise respiratory quotient was lower during RM-493 treatment (0.833 ± 0.021 vs 0.848 ± 0.022, P = .02). No adverse effect on heart rate or blood pressure was observed.
CONCLUSIONS - Short-term administration of the MC4R agonist RM-493 increases REE and shifts substrate oxidation to fat in obese individuals.
0 Communities
1 Members
0 Resources
16 MeSH Terms
A pilot randomized crossover trial assessing the safety and short-term effects of pomegranate supplementation in hemodialysis patients.
Rivara MB, Mehrotra R, Linke L, Ruzinski J, Ikizler TA, Himmelfarb J
(2015) J Ren Nutr 25: 40-9
MeSH Terms: Aged, Beverages, Biomarkers, C-Reactive Protein, Cross-Over Studies, Dietary Supplements, F2-Isoprostanes, Female, Humans, Inflammation, Interleukin-10, Interleukin-1beta, Interleukin-6, Linear Models, Lipids, Male, Middle Aged, Oxidative Stress, Pilot Projects, Plant Preparations, Prospective Studies, Punicaceae, Renal Dialysis, Sensitivity and Specificity, Treatment Outcome, Tumor Necrosis Factor-alpha
Show Abstract · Added September 29, 2014
OBJECTIVE - Oxidative stress and systemic inflammation are highly prevalent in patients undergoing maintenance hemodialysis (MHD) and are linked to excess cardiovascular risk. This study examined whether short-term supplementation with pomegranate juice and extract is safe and well tolerated by MHD patients. The secondary aim was to assess the effect of pomegranate supplementation on oxidative stress, systemic inflammation, monocyte function, and blood pressure.
DESIGN - Prospective, randomized, crossover, pilot clinical trial (NCT01562340).
SETTING - The study was conducted from March to October 2012 in outpatient dialysis facilities in the Seattle metropolitan area.
SUBJECTS - Twenty-four patients undergoing MHD (men, 64%; mean age, 61 ± 14 years) were randomly assigned to receive pomegranate juice or extract during a 4-week intervention period. After a washout period, all patients received the alternative treatment during a second 4-week intervention period.
INTERVENTION - Patients assigned to receive pomegranate juice received 100 mL of juice before each dialysis session. Patients assigned to receive pomegranate extract were given 1,050 mg of extract daily.
MAIN OUTCOME MEASURES - The main outcome measures were safety and tolerability of pomegranate juice and extract. Additional secondary outcomes assessed included serum lipids, laboratory biomarkers of inflammation (C-reactive protein and interleukin 6) and oxidative stress (plasma F2 isoprostanes and isofurans), monocyte cytokine production, and predialysis blood pressure.
RESULTS - Both pomegranate juice and extract were safe and well tolerated by study participants. Over the study period, neither treatment had a significant effect on lipid profiles, plasma C-reactive protein, interleukin 6, F2-isoprostane or isofuran concentrations, predialysis systolic or diastolic blood pressure nor changed the levels of monocyte cytokine production.
CONCLUSIONS - Both pomegranate juice and extract are safe and well tolerated by patients undergoing MHD but do not influence markers of inflammation or oxidative stress nor affect predialysis blood pressure.
Copyright © 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
0 Communities
1 Members
0 Resources
26 MeSH Terms
Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm.
Devin JK, Pretorius M, Nian H, Yu C, Billings FT, Brown NJ
(2014) J Am Heart Assoc 3:
MeSH Terms: Adult, Cross-Over Studies, Dipeptidyl-Peptidase IV Inhibitors, Double-Blind Method, Female, Forearm, Glucagon-Like Peptide 1, Healthy Volunteers, Humans, Male, Middle Aged, Natriuretic Peptide, Brain, Pyrazines, Regional Blood Flow, Sitagliptin Phosphate, Triazoles, Vasodilation
Show Abstract · Added January 20, 2015
BACKGROUND - Dipeptidyl-peptidase 4 (DPP4) inhibitors improve glycemic control in patients with diabetes mellitus by preventing the degradation of glucagon-like peptide-1 (GLP-1). GLP-1 causes vasodilation in animal models but also increases sympathetic activity; the effect of GLP-1 in the human vasculature and how it is altered by DPP4 inhibition is not known. DPP4 also degrades the vasodilator brain natriuretic peptide (BNP) to a less potent metabolite. This study tested the hypothesis that DPP4 inhibition potentiates the vasodilator responses to GLP-1 and BNP in the human forearm.
METHOD AND RESULTS - Seventeen healthy subjects participated in this randomized, double-blinded, placebo-controlled crossover study. On each study day, subjects received DPP4 inhibitor (sitagliptin 200 mg by mouth) or placebo. Sitagliptin increased forearm blood flow and decreased forearm vascular resistance without affecting mean arterial pressure and pulse. GLP-1 and BNP were infused in incremental doses via brachial artery. Venous GLP-1 concentrations were significantly higher during sitagliptin use, yet there was no effect of GLP-1 on forearm blood flow in the presence or absence of sitagliptin. BNP caused dose-dependent vasodilation; however, sitagliptin did not affect this response. GLP-1 and BNP had no effect on net norepinephrine release.
CONCLUSIONS - These data suggest that GLP-1 does not act as a direct vasodilator in humans and does not contribute to sympathetic activation. Sitagliptin does not regulate vascular function in healthy humans by affecting the degradation of GLP-1 and BNP.
CLINICAL TRIAL REGISTRATION URL - www.clinicaltrials.gov/ Unique identifier: NCT01413542.
© 2014 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.
0 Communities
2 Members
0 Resources
17 MeSH Terms
Biologic comparison of inhaled insulin formulations: Exubera™ and novel spray-dried engineered particles of dextran-10.
Kuehl PJ, Cherrington A, Dobry DE, Edgerton D, Friesen DT, Hobbs C, Leach CL, Murri B, Neal D, Lyon DK, Vodak DT, Reed MD
(2014) AAPS PharmSciTech 15: 1545-50
MeSH Terms: Administration, Inhalation, Aerosols, Animals, Area Under Curve, Blood Glucose, Chemistry, Pharmaceutical, Cross-Over Studies, Dextrans, Dogs, Drug Carriers, Female, Hypoglycemic Agents, Insulin, Metabolic Clearance Rate, Particle Size, Powders, Technology, Pharmaceutical
Show Abstract · Added February 12, 2015
Inhaled peptides and proteins have promise for respiratory and systemic disease treatment. Engineered spray-dried powder formulations have been shown to stabilize peptides and proteins and optimize aerosol properties for pulmonary delivery. The current study was undertaken to investigate the in vitro and in vivo inhalation performance of a model spray-dried powder of insulin and dextran 10 in comparison to Exubera™. Dextrans are a class of glucans that are generally recognized as safe with optimum glass transition temperatures well suited for spray drying. A 70% insulin particle loading was prepared by formulating with 30% (w/v) dextran 10. Physical characterization revealed a "raisin like" particle. Both formulations were generated to produce a similar bimodal particle size distribution of less than 3.5 μm MMAD. Four female Beagle dogs were exposed to each powder in a crossover design. Similar presented and inhaled doses were achieved with each powder. Euglycemia was achieved in each dog prior and subsequent to dosing and blood samples were drawn out to 245 min post-exposure. Pharmacokinetic analyses of post-dose insulin levels were similar for both powders. Respective dextran 10-insulin and Exubera exposures were similar producing near identical area under the curve (AUC), 7,728 ± 1,516 and 6,237 ± 2,621; concentration maximums (C max), 126 and 121 (μU/mL), and concentration-time maximums, 20 and 14 min, respectively. These results suggest that dextran-10 and other dextrans may provide a novel path for formulating peptides and proteins for pulmonary delivery.
0 Communities
2 Members
0 Resources
17 MeSH Terms
Dietary sodium restriction decreases insulin secretion without affecting insulin sensitivity in humans.
Luther JM, Byrne LM, Yu C, Wang TJ, Brown NJ
(2014) J Clin Endocrinol Metab 99: E1895-902
MeSH Terms: Adult, Aldosterone, Blood Glucose, Cross-Over Studies, Diet, Sodium-Restricted, Double-Blind Method, Female, Glucose Clamp Technique, Healthy Volunteers, Humans, Hyperglycemia, Insulin, Insulin Resistance, Insulin Secretion, Male, Renin, Renin-Angiotensin System, Sodium, Dietary
Show Abstract · Added October 27, 2014
CONTEXT - Interruption of the renin-angiotensin-aldosterone system prevents incident diabetes in high-risk individuals, although the mechanism remains unclear.
OBJECTIVE - To test the hypothesis that activation of the endogenous renin-angiotensin-aldosterone system or exogenous aldosterone impairs insulin secretion in humans.
DESIGN - We conducted a randomized, blinded crossover study of aldosterone vs vehicle and compared the effects of a low-sodium versus a high-sodium diet.
SETTING - Academic clinical research center.
PARTICIPANTS - Healthy, nondiabetic, normotensive volunteers.
INTERVENTIONS - Infusion of exogenous aldosterone (0.7 μg/kg/h for 12.5 h) or vehicle during low or high sodium intake. Low sodium (20 mmol/d; n = 12) vs high sodium (160 mmol/d; n = 17) intake for 5-7 days.
MAIN OUTCOME MEASURES - Change in acute insulin secretory response assessed during hyperglycemic clamps while in sodium balance during a low-sodium vs high-sodium diet during aldosterone vs vehicle.
RESULTS - A low-sodium diet increased endogenous aldosterone and plasma renin activity, and acute glucose-stimulated insulin (-16.0 ± 5.6%; P = .007) and C-peptide responses (-21.8 ± 8.4%; P = .014) were decreased, whereas the insulin sensitivity index was unchanged (-1.0 ± 10.7%; P = .98). Aldosterone infusion did not affect the acute insulin response (+1.8 ± 4.8%; P = .72) or insulin sensitivity index (+2.0 ± 8.8%; P = .78). Systolic blood pressure and serum potassium were similar during low and high sodium intake and during aldosterone infusion.
CONCLUSIONS - Low dietary sodium intake reduces insulin secretion in humans, independent of insulin sensitivity.
0 Communities
2 Members
0 Resources
18 MeSH Terms